Researchers presented pooled data at ASH indicating that minimal residual disease (MRD) negativity correlates with longer overall survival in acute myeloid leukemia and could serve as a surrogate endpoint for accelerated approval. The dataset, described as the largest prospective pooled MRD analysis in AML, supports use of multiparameter flow cytometry–based MRD measurements prior to consolidation as an intermediate marker. Regulators have already accepted MRD as a surrogate in other hematologic malignancies; this ASH evidence may encourage sponsors to design trials that use MRD to shorten development timelines. For drug developers, adopting MRD endpoints could materially change go/no‑go decisions and licensing strategies in AML.